Format

Send to

Choose Destination
Vaccine. 2012 Jul 6;30(32):4757-61. doi: 10.1016/j.vaccine.2012.05.044. Epub 2012 May 29.

Two decades of hepatitis B vaccination in mentally retarded patients: effectiveness, antibody persistence and duration of immune memory.

Author information

1
Centre for the Evaluation of Vaccination, Vaccine & Infectious Disease Institute, Faculty of Medicine and Health Sciences, University of Antwerp, Universiteitsplein 1, 2610 Antwerpen (Wilrijk), Belgium. tessa.braeckman@ua.ac.be

Abstract

INTRODUCTION:

Institutionalized mentally retarded subjects are well-known to be at-risk for HBV infection. We studied the persistence of vaccine-induced anti-HBs antibodies and the robustness of the HBsAg-specific immune memory in this population, 18-20 years after the first vaccine dose.

MATERIALS AND METHODS:

Non-immune residents of 4 institutions were immunized in 1984-1986. In 2004, 207 subjects were bled to determine humoral and cellular immune memory. Immune response to a booster dose was evaluated in subjects with anti-HBs level <100 IU/L.

RESULTS:

Four subjects showed anti-HBc seroconversion, without clinical implications. Pre-booster anti-HBs levels <100 IU/L were found in 45 subjects (22%); 34/39 (87%) responded with a rapid and high anti-HBs titer to the booster dose. Robust T and B cell memory was present pre- and post-booster.

DISCUSSION AND CONCLUSION:

Overall results confirm that hepatitis B vaccines are highly effective and immunogenic, and confer long-term persistence of antibodies and immune memory in an at-risk population.

PMID:
22652400
DOI:
10.1016/j.vaccine.2012.05.044
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center